Monoclonal antibody-based therapies for microbial diseases
Identifieur interne : 000158 ( Ncbi/Curation ); précédent : 000157; suivant : 000159Monoclonal antibody-based therapies for microbial diseases
Auteurs : Carolyn Saylor [États-Unis] ; Ekaterina Dadachova [États-Unis] ; Arturo Casadevall [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2009.
Abstract
The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.
Url:
DOI: 10.1016/j.vaccine.2009.09.105
PubMed: 20006139
PubMed Central: 2810317
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000377
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000377
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000621
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000158
Links to Exploration step
PMC:2810317Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Monoclonal antibody-based therapies for microbial diseases</title>
<author><name sortKey="Saylor, Carolyn" sort="Saylor, Carolyn" uniqKey="Saylor C" first="Carolyn" last="Saylor">Carolyn Saylor</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Microbiology and Immunology, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dadachova, Ekaterina" sort="Dadachova, Ekaterina" uniqKey="Dadachova E" first="Ekaterina" last="Dadachova">Ekaterina Dadachova</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Microbiology and Immunology, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A2">Department of Nuclear Medicine, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Casadevall, Arturo" sort="Casadevall, Arturo" uniqKey="Casadevall A" first="Arturo" last="Casadevall">Arturo Casadevall</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Microbiology and Immunology, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A3">Department of Medicine of the Albert Einstein College of Medicine, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine of the Albert Einstein College of Medicine, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20006139</idno>
<idno type="pmc">2810317</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810317</idno>
<idno type="RBID">PMC:2810317</idno>
<idno type="doi">10.1016/j.vaccine.2009.09.105</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">000377</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000377</idno>
<idno type="wicri:Area/Pmc/Curation">000377</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000377</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000621</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000621</idno>
<idno type="wicri:Area/Ncbi/Merge">000158</idno>
<idno type="wicri:Area/Ncbi/Curation">000158</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Monoclonal antibody-based therapies for microbial diseases</title>
<author><name sortKey="Saylor, Carolyn" sort="Saylor, Carolyn" uniqKey="Saylor C" first="Carolyn" last="Saylor">Carolyn Saylor</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Microbiology and Immunology, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dadachova, Ekaterina" sort="Dadachova, Ekaterina" uniqKey="Dadachova E" first="Ekaterina" last="Dadachova">Ekaterina Dadachova</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Microbiology and Immunology, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A2">Department of Nuclear Medicine, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Casadevall, Arturo" sort="Casadevall, Arturo" uniqKey="Casadevall A" first="Arturo" last="Casadevall">Arturo Casadevall</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Microbiology and Immunology, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A3">Department of Medicine of the Albert Einstein College of Medicine, Bronx, NY 10461, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine of the Albert Einstein College of Medicine, Bronx, NY 10461</wicri:regionArea>
<wicri:noRegion>NY 10461</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000158 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000158 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV1 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:2810317 |texte= Monoclonal antibody-based therapies for microbial diseases }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:20006139" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a CovidV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |